ResearcherUniversity of California, Los AngelesNo recent work listed
Juehua Yu
Matched on ORCID iD 0000-0002-1661-0503; OpenAlex author ID A5102816962. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 1 paper
Papers 6
- Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12864-021-08137-5↗
- Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2020.08.002↗
- Long noncoding RNA XIST regulates the EGF receptor to promote TGF-β1-induced epithelial-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1139/bcb-2018-0274↗
- Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Co-author DOI 10.3892/or.2020.7810↗
- A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. First author DOI 10.1016/j.canlet.2018.01.007↗
- Pancreatic cancer actionable genes in precision medicine and personalized surgery. Co-author DOI 10.1016/j.surge.2016.05.002↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Francis Charles Brunicardi · 4 shared papers, 2017–2020 · strength 0.37
- Paper Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcino… DOI 10.1016/j.canlet.2020.08.002↗
- Paper Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. DOI 10.3892/or.2020.7810↗
- Paper A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. DOI 10.1016/j.canlet.2018.01.007↗
- Shi‐He Liu · 3 shared papers, 2018–2020 · strength 0.28
- Paper Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcino… DOI 10.1016/j.canlet.2020.08.002↗
- Paper Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. DOI 10.3892/or.2020.7810↗
- Paper A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. DOI 10.1016/j.canlet.2018.01.007↗
- John J. Nemunaitis · 3 shared papers, 2017–2020 · strength 0.27
- Paper Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcino… DOI 10.1016/j.canlet.2020.08.002↗
- Paper A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. DOI 10.1016/j.canlet.2018.01.007↗
- Paper Pancreatic cancer actionable genes in precision medicine and personalized surgery. DOI 10.1016/j.surge.2016.05.002↗
- Hongjin Wu · 2 shared papers, 2020–2021 · strength 0.23
- Yu Xu · 2 shared papers, 2020 · strength 0.22
- Paper Long noncoding RNA XIST regulates the EGF receptor to promote TGF-β1-induced epithelial-mesenchymal transition in pancr… DOI 10.1139/bcb-2018-0274↗
- Paper Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. DOI 10.3892/or.2020.7810↗
- Kunhua Wang · 2 shared papers, 2020 · strength 0.22
- Paper Long noncoding RNA XIST regulates the EGF receptor to promote TGF-β1-induced epithelial-mesenchymal transition in pancr… DOI 10.1139/bcb-2018-0274↗
- Paper Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. DOI 10.3892/or.2020.7810↗
- Lei Zou · 2 shared papers, 2020 · strength 0.22
- Paper Long noncoding RNA XIST regulates the EGF receptor to promote TGF-β1-induced epithelial-mesenchymal transition in pancr… DOI 10.1139/bcb-2018-0274↗
- Paper Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. DOI 10.3892/or.2020.7810↗
- Xiaosong Zhu · 1 shared paper, 2021 · strength 0.13
- Jeffrey M. Sutton MD · 1 shared paper, 2020 · strength 0.10
- Justin F. Creeden · 1 shared paper, 2020 · strength 0.10
- Cheng Yeh Chen · 1 shared paper, 2020 · strength 0.10
- Enrique Rozengurt · 1 shared paper, 2017 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.